Related Experiment Video

Updated: Aug 16, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

The potential impact of nanomedicine on COVID-19-induced thrombosis

Peije Russell1,2,3, Lars Esser1,2, Christoph E Hagemeyer4

  • 1Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Nature Nanotechnology
|December 19, 2022
PubMed

Insights

Nanomedicine offers novel solutions for COVID-19-induced thromboinflammation, addressing limitations of conventional treatments. This approach enables targeted drug delivery, potentially leading to safer and more effective therapies for cardiovascular complications.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cardiovascular Medicine
  • Infectious Diseases

Background:

  • Coronavirus disease 2019 (COVID-19) is associated with severe thromboembolic events, including pulmonary embolisms, ischemic stroke, and myocardial infarctions.
  • COVID-19 survivors face an elevated long-term risk of cardiovascular diseases, underscoring gaps in understanding and treating COVID-19-induced thromboinflammation.
  • Current anti-thrombotic therapies have limitations; conventional anticoagulants are insufficient, and thrombolytics carry significant bleeding risks.

Purpose of the Study:

  • To review promising nanocarrier systems and design strategies for developing nanomedicine to combat COVID-19-induced thromboinflammation.
  • To explore the potential of nanomedicine in overcoming the challenges posed by the complex pathophysiology of immunothrombosis.
  • To investigate dual-therapeutic nanomedicine approaches combining antiviral and immunosuppressive agents.

Main Methods:

  • Literature review of existing nanocarrier systems and their potential applications in treating thromboinflammation.
  • Analysis of nanomedicine design strategies for targeted and on-demand drug delivery.
  • Exploration of dual-therapeutic nanomedicine concepts for synergistic effects.

Main Results:

  • Nanomedicine platforms demonstrate potential for protecting therapeutics and enabling targeted delivery in thromboinflammatory conditions.
  • Various nanocarrier systems and design strategies are identified as promising for COVID-19-related cardiovascular complications.
  • Dual-therapeutic approaches integrating antiviral and immunosuppressive functions show potential for enhanced efficacy.

Conclusions:

  • Nanomedicine presents a significant opportunity to develop advanced therapeutic options for COVID-19-induced thromboinflammation.
  • Targeted, side-effect-free nanomedicine treatments could revolutionize the management of cardiovascular sequelae of COVID-19.
  • Further research into nanomedicine holds promise for mitigating the long-term cardiovascular impact of the pandemic.

More Related Videos

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

10.0K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
827
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
16
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
151
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
585